Signaling by FGFR1 fusion mutants

8p11 myeloproliferative syndrome (EMS) is an aggressive disorder that is associated with a translocation event at the FGFR1 gene on chromosome 8p11. Typical symptoms upon diagnosis include eosinophilia and associated T-cell lymphoblastic lymphoma; the disease rapidly advances to acute leukemia, usually of myeloid lineage. At present the only effective treatment is allogenic stem cell transplantation (reviewed in Jackson, 2010). <br><br>At the molecular level, EMS appears to be caused by translocation events on chromosome 8 that create gene fusions between the intracellular domain of FGFR1 and an N-terminal partner gene that encodes a dimerization domain. The resulting fusion protein dimerizes in a ligand-independent fashion based the N-terminal domain provided by the partner protein and stimulates constititutive downstream FGFR1 signaling without altering the intrisic kinase activity of the receptor. To date, 11 partner genes have been identified: ZMYM2, FGFR1OP, FGFR1OP2, HERVK, TRIM24, CUX1, BCR, CEP110, LRRFIP1, MYO18A and CPSF6, although not all have been functionally characterized (reviewed in Jackson, 2010, Turner and Grose, 2010; Wesche, 2011). <br>Where examined, cell lines carrying FGFR1 fusion genes have been shown to be transforming and to support IL3-independent proliferation through anti-apoptotic, prosurvival pathways(Lelièvre, 2008; Ollendorff, 1999; Chase, 2007; Guasch, 2001; Wasag 2011; Roumiantsev, 2004; Demiroglu, 2001; Smedley, 1999). Signaling appears to occur predominantly through PLCgamma, PI3K and STAT signaling, with a more minor contribution from MAPK activation. Because the fusion proteins lack the FRS2-binding site, the mechanism of MAPK activation is unclear. Recruitment of GRB2:SOS1 through recruitment of SHC is one possibility (Guasch, 2001). Edited: Rothfels, K, 2012-05-16 Authored: Rothfels, K, 2012-02-09 Reviewed: Ezzat, S, 2012-05-15

http://purl.obolibrary.org/obo/HINO_0016292

8p11 myeloproliferative syndrome (EMS) is an aggressive disorder that is associated with a translocation event at the FGFR1 gene on chromosome 8p11. Typical symptoms upon diagnosis include eosinophilia and associated T-cell lymphoblastic lymphoma; the disease rapidly advances to acute leukemia, usually of myeloid lineage. At present the only effective treatment is allogenic stem cell transplantation (reviewed in Jackson, 2010).

At the molecular level, EMS appears to be caused by translocation events on chromosome 8 that create gene fusions between the intracellular domain of FGFR1 and an N-terminal partner gene that encodes a dimerization domain. The resulting fusion protein dimerizes in a ligand-independent fashion based the N-terminal domain provided by the partner protein and stimulates constititutive downstream FGFR1 signaling without altering the intrisic kinase activity of the receptor. To date, 11 partner genes have been identified: ZMYM2, FGFR1OP, FGFR1OP2, HERVK, TRIM24, CUX1, BCR, CEP110, LRRFIP1, MYO18A and CPSF6, although not all have been functionally characterized (reviewed in Jackson, 2010, Turner and Grose, 2010; Wesche, 2011).
Where examined, cell lines carrying FGFR1 fusion genes have been shown to be transforming and to support IL3-independent proliferation through anti-apoptotic, prosurvival pathways(Lelièvre, 2008; Ollendorff, 1999; Chase, 2007; Guasch, 2001; Wasag 2011; Roumiantsev, 2004; Demiroglu, 2001; Smedley, 1999). Signaling appears to occur predominantly through PLCgamma, PI3K and STAT signaling, with a more minor contribution from MAPK activation. Because the fusion proteins lack the FRS2-binding site, the mechanism of MAPK activation is unclear. Recruitment of GRB2:SOS1 through recruitment of SHC is one possibility (Guasch, 2001).

Edited: Rothfels, K, 2012-05-16

Authored: Rothfels, K, 2012-02-09

Reviewed: Ezzat, S, 2012-05-15

Pubmed17698633

Pubmed20226962

Pubmed15050920

Pubmed21330321

Pubmed11739186

Reactome, http://www.reactome.org

Pubmed21367659

Pubmed11689702

Pubmed18412956

Pubmed10935490

Pubmed21711248

Pubmed20094046

Pubmed10480903

Signaling by FGFR1 fusion mutants

http://purl.obolibrary.org/obo/NCBITaxon_9606

HINO:0016292

Signaling by FGFR1 fusion mutants

Reactome Database ID Release 431839117

ReactomeREACT_121141

http://purl.obolibrary.org/obo/INO_0000021

http://purl.obolibrary.org/obo/HINO_0008618

http://purl.obolibrary.org/obo/HINO_0008626

http://purl.obolibrary.org/obo/HINO_0008625

http://purl.obolibrary.org/obo/HINO_0008627

http://purl.obolibrary.org/obo/HINO_0008621

http://purl.obolibrary.org/obo/HINO_0008624

http://purl.obolibrary.org/obo/HINO_0008117

http://purl.obolibrary.org/obo/HINO_0008110

http://purl.obolibrary.org/obo/HINO_0008114

http://purl.obolibrary.org/obo/HINO_0008113

http://purl.obolibrary.org/obo/HINO_0008112

http://purl.obolibrary.org/obo/HINO_0008111

http://purl.obolibrary.org/obo/HINO_0008116

http://purl.obolibrary.org/obo/HINO_0008118

http://purl.obolibrary.org/obo/HINO_0008115

http://purl.obolibrary.org/obo/HINO_0008119

http://purl.obolibrary.org/obo/HINO_0008579